Preclinical News and Research

RSS

Experimental drug may stop life-threatening muscle wasting associated with advanced cancers

New data describes how an experimental drug can stop life-threatening muscle wasting (cachexia) associated with advanced cancers and restore muscle health. The experimental agent, known as AR-42 while in testing, was developed and tested in preclinical studies at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.

25 Nov 2015

Crucial tumor-suppressing gene protects immune attack against lung cancer

A crucial tumor-thwarting gene protects an immune attack against lung cancer by blocking the key to an off switch on T cells, the customized warriors of the immune system, a team led by researchers at The University of Texas MD Anderson Cancer Center reports in the Journal of the National Cancer Institute.

21 Nov 2015

TSRI researchers awarded $1.6 million grant to advance preclinical studies of potential heroin vaccine

Now researchers at The Scripps Research Institute have been awarded a prestigious Translational Avant-Garde Award, which supports the development of medications for substance abuse disorders, from the National Institutes of Health National Institute on Drug Abuse.

20 Nov 2015

Urine-derived iPSCs model could help predict patient response to cholesterol-lowering drugs

We all know how important it is to keep our levels of blood cholesterol - especially the 'bad' variety - in check with a healthy diet and regular exercise. Although cholesterol is a key structural component of cell membranes and is vital for the biosynthesis of certain hormones and vitamins, high levels can lead to the formation of arterial plaques, which are a major risk factor for coronary heart disease.

20 Nov 2015

Hapten Sciences plans to initiate Phase 1 clinical trial for new poison ivy vaccine

Hapten Sciences, Inc., a privately held biotechnology company, announced today that it has filed an Investigational New Drug (IND) application and is now planning to initiate dosing of healthy volunteers in a first-in-human Phase 1 clinical trial of its lead product candidate, PDC-APB, a novel, first-in-class, compound in development for a new indication to prevent contact dermatitis due to exposure to poison ivy, oak, and sumac.

19 Nov 2015

Georgia State University researchers develop a method to better trace and treat cancer

A method to better trace changes in cancers and treatment of the prostate and lung without the limitations associated with radiation has been developed by Georgia State University researchers.

18 Nov 2015

USC discoveries propose promising method to eliminate pain associated with tooth decay

Dual discoveries at USC propose a promising method to regrow nonliving hard tissue, lessening or even eliminating pain associated with tooth decay, which the National Institutes of Health calls the most prevalent chronic disease.

18 Nov 2015

Drug prevents onset of cognitive and cellular effects in mouse model of Alzheimer’s disease

In a novel animal study design that mimicked human clinical trials, researchers at University of California, San Diego School of Medicine report that long-term treatment using a small molecule drug that reduces activity of the brain's stress circuitry significantly reduces Alzheimer's disease (AD) neuropathology and prevents onset of cognitive impairment in a mouse model of the neurodegenerative condition.

17 Nov 2015

MIPT researchers patent graphene biosensors that may accelerate development of novel drugs

The US Patent Office has recently published the patent application (no. US 2015/0301039), which was filed by the MIPT in May this year and is titled Biological Sensor and a Method of the Production of Biological Sensor. In Russia, this development is already protected by the patent No. 2527699 with a priority date of February 20, 2013. The key feature of the sensor is the use of a linking layer for biomolecule immobilization comprising a thin film of graphene or graphene oxide.

17 Nov 2015

Analyzing potential TB vaccine

When results from a landmark tuberculosis vaccine trial in Cape Town, South Africa were published in The Lancet in February 2013, the headlines were grim, despite hopes that the trial would point toward a successful way to thwart one of the globe's biggest public health threats.

13 Nov 2015

Idera begins enrollment in IMO-8400 Phase 2 clinical trial for treatment of dermatomyositis

Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing Toll-like receptor (TLR) and RNA therapeutics for patients with cancer and rare diseases, today announced that the company has commenced enrollment in a Phase 2 clinical trial of IMO-8400, an investigational TLR 7, 8 and 9 antagonist, in patients with dermatomyositis. Dermatomyositis is a rare and debilitating inflammatory muscle and skin disease associated with significant morbidity, decreased quality of life and an increased risk of premature death.

10 Nov 2015

Drug compounds target multiple pathways associated with myotonic dystrophy type 1

Efforts to treat myotonic dystrophy type 1, the most common form of muscular dystrophy, are in their infancy. In a new study, researchers report they have added new capabilities to an experimental drug agent that previously defeated only one of DM1's many modes of action. Their retooled compounds interrupt the disease's pathology in three ways.

10 Nov 2015

AACR rapid and dramatic responses in TRK fusion patients

Loxo Oncology, Inc., a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, today announced new results from its Phase 1 open-label, dose-escalation trial of LOXO-101, a selective inhibitor of tropomyosin receptor kinase (TRK) signaling molecules, and the first preclinical data for its RET and FGFR programs. The data are being presented at the 2015 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston.

9 Nov 2015

Agios announces data from dose-escalation phase 1 study of AG-120 in patients with IDH1 mutant positive advanced solid tumors

Agios Pharmaceuticals, Inc., a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced the first data from the dose-escalation portion of the ongoing Phase 1 study evaluating single agent AG-120, a first-in-class, oral, selective, potent inhibitor of mutant isocitrate dehydrogenase-1 (IDH1), in advanced solid tumors. The data are being presented today at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston. AG-120 is being developed in collaboration with Celgene.

9 Nov 2015

Key part of MRSA vaccine puzzle unearthed

Immunologists from Trinity College Dublin have unearthed a key piece of the MRSA vaccine puzzle by identifying specific ‘helper’ cells whose role in the immune response is critical in affecting infection outcomes.

9 Nov 2015

MD Anderson Cancer Center, CytomX to study probody-enabled CAR-NK cell therapies

CytomX Therapeutics, a biopharmaceutical company developing investigational Probody™ therapeutics for the treatment of cancer, today entered into a collaboration with The University of Texas MD Anderson Cancer Center to research Probody-enabled chimeric antigen receptor natural killer (CAR-NK) cell therapies, to be known as ProCAR-NK cell therapies.

6 Nov 2015

GHIT Fund invests $10.7 million to fight malaria, TB, leishmaniasis and dengue

The Global Health Innovative Technology Fund, which in the last two years has invested US$43 million to develop innovative tools for fighting diseases worldwide, today announced it is investing $10.7 million at multiple points in the product development pipeline to seek new interventions for malaria, tuberculosis (TB), leishmaniasis and dengue.

5 Nov 2015

ReDy receives CE clearance for third-generation Renal Denervation System

Renal Dynamics' third-generation Renal Denervation System received CE clearance and is now commercially available in Europe for treatment of Resistant Hypertension. The ReDy Renal Denervation System is based on a novel multi-electrode ablation technology that delivers a pre-determined RF ablation set with a single positioning.

4 Nov 2015

Samumed to present preclinical and clinical data on Wnt pathway for OA treatment at ACR 2015

Samumed, LLC, a leader in tissue regeneration, announced today that it will present preclinical and clinical data on a small molecule modulator of the Wnt pathway (SM04690, an investigational new drug) for potential disease modifying treatment of osteoarthritis (OA) of the knee at 2015 American College of Rheumatology Annual Meeting.

4 Nov 2015

New computational method helps predict adverse drug reaction better than traditional computing methods

A new integrated computational method helps predicting adverse drug reaction--which are often lethal--more reliably than with traditional computing methods. This improved ability to foresee the possible adverse effects of drugs may entail saving many lives in the future.

4 Nov 2015

Preclinical News and Research

Experimental drug may stop life-threatening muscle wasting associated with advanced cancers

Crucial tumor-suppressing gene protects immune attack against lung cancer

TSRI researchers awarded $1.6 million grant to advance preclinical studies of potential heroin vaccine

Urine-derived iPSCs model could help predict patient response to cholesterol-lowering drugs

Hapten Sciences plans to initiate Phase 1 clinical trial for new poison ivy vaccine

Georgia State University researchers develop a method to better trace and treat cancer

USC discoveries propose promising method to eliminate pain associated with tooth decay

Drug prevents onset of cognitive and cellular effects in mouse model of Alzheimer’s disease

MIPT researchers patent graphene biosensors that may accelerate development of novel drugs

Analyzing potential TB vaccine

Idera begins enrollment in IMO-8400 Phase 2 clinical trial for treatment of dermatomyositis

Drug compounds target multiple pathways associated with myotonic dystrophy type 1

AACR rapid and dramatic responses in TRK fusion patients

Agios announces data from dose-escalation phase 1 study of AG-120 in patients with IDH1 mutant positive advanced solid tumors

Key part of MRSA vaccine puzzle unearthed

MD Anderson Cancer Center, CytomX to study probody-enabled CAR-NK cell therapies

GHIT Fund invests $10.7 million to fight malaria, TB, leishmaniasis and dengue

ReDy receives CE clearance for third-generation Renal Denervation System

Samumed to present preclinical and clinical data on Wnt pathway for OA treatment at ACR 2015

New computational method helps predict adverse drug reaction better than traditional computing methods

New Approach Methodologies, the 3Rs and Multimodal Imaging in Preclinical Research - eBook eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics